Trial Information

A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)

Official Title: A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)

Summary

The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI). MCI is now recognized as a precursor to AD and clinical tools are available to assess cognitive performance at this earlier stage. Ladostigil is currently under investigation for the treatment of AD. In this study, the investigators will be examining ladostigil at a lower dose level. At this dose level, ladostigil has been shown to reduce signs of early memory loss in animals. Thus, in this study the investigators are attempting to determine if earlier invention with a lower dose of ladostigil will significantly reduce initial memory loss and delay the subsequent progression to more serious cognitive dysfunction.

Phase: Phase 2

Sponsor: Avraham Pharmaceuticals Ltd

Locations (12)

Country	State	City	Zip	Facility and Contact
Austria		Graz	8036	Medizinische Universitat Graz, Abteilung fur Neurologie Birgit Reinhart 316 385 833 96 birgit.reinhart@medunigraz.at Reinhold Schmidt, MD Principal Investigator
Austria		Hall in Tirol	6060	Landeskrankenhaus Hall, Memory Klinik Douglas Imarhiagbe 5050 488 266 douglas.imarhiagbe@tilak.at Douglas Imarhiagbe Principal Investigator
Austria		Wien	1130	Privatordination Rainer Michael Rainer, MD 1 319 1466 michael.rainer@wienkav.at Michael Rainer, MD Principal Investigator
Germany		Berlin	13088	Studienambulanz St. Joseph Krankenhaus Berlin, Emovis GmbH Daniel Schulz 30 310 136 77 daniel.schulz@emovis.de Bettina Bergtholdt, MD Principal Investigator
Germany		Magdeburg	30120	Otto-von-Guericke-Universitat, Universitatsklinik fur Neurologie und fur Stereotaktische Martina Leucke 391 67 144 13 martina.leucke@med.ovgu.de Daniel Bittner, MD Principal Investigator
Germany		Westerstede	26655	Studienzentrum Nordwest Joachim Springub, MD 4488 521 500 joachim.springub@ewetel.net Joachim Springub, MD Principal Investigator
Israel		Beersheva	84170	Department of Geriatrics and Memory Clinic, Mental Health Center, Israel Tzvi Dwolatzky 972-8-6401765 memory.clinic@pbsh.Health.gov.il Tzvi Dwolatzky, MD Principal Investigator
Israel		Haifa	31096	Cognitive Neurology Unit, Rambam Health Care Campus Yehudit Aharon-Peretz 972-4-8543191 memory@rambam.health.gov.il Yehudit Aharon-Peretz, MD Principal Investigator
Israel		Haifa	34362	Cognitive Clinic, Department of Geriatrics, Carmel Medical Center Gary Sinoff 972-4-8250552 cato_sinoff@clalit.org.il Gary Sinof, MD Principal Investigator
Israel		Jerusalem	91240	Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, PO Box 24035 Zeev Meiner 972-2-5844474 MEINER@hadassah.org.il Zeev Miner, MD Principal Investigator
Israel		Ramat Gan	52621	Memory Clinic, Sheba Medical Center at Tel Hashomer Ramit Ravona 972-3-5303349 ramitrs@hotmail.com Ramit Ravona, MD Principal Investigator
Israel		Tel Aviv	64239	Center for Memory and Attention Disorders, Department of Neurology, Sourasky Medical Center Elissa Ash, MD 972-3-6973698 elissaa@tasmc.health.gov.il Elissa Ash, MD Principal Investigator

NCT ID:NCT01429623

Date Last Changed: March 4, 2012